Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Manufacturing
  • Health
  • Technology
  • Book Release
  • Financial
ncarol.com

Universal Sequencing Technology Corporation Launches High-Throughput Solution For Microbial WGS Library Preparation
ncarol.com/10214820

Trending...
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Gabby Press Earns High Praise From Feathered Quill About the Unregulated Dangers of Second Generation Corporate AI
Universal Sequencing Technology Corporation
CARLSBAD, Calif. - ncarol.com -- Universal Sequencing Technology Corporation (UST), a global leader in genomic sequencing innovations, announced today the release of a high throughput microbial WGS library preparation kit enabling 2nd-generation short-read sequencers to produce long-range results in a much affordable price for microbial genomes.

With this special high throughput kit, users can pool more microbial samples in one sequencing run in combination with our 96-well plate multiplexing primers, which includes 10-base indexes and significantly reduces NGS library preparation and sequencing costs.

Researchers will now be able to take advantage of the ultra-long linked-read results to provide unparalleled genomic information with up to 200Kb gDNA fragments for microbial genome analyses.

With TELL-Seq technology, we've made NGS library preparation easy. Our products effectively improve performance, process time, and budget across a broad range of sample types with a proven track record.

Dr. Tom Chen, Chief Scientific Officer of UST, stated, "We are further streamlining the TELL-seq workflow with reduced cost per reaction and expanded throughput in response to increased customer demands."

More on ncarol.com
  • Santa Your Way Announces Official 2026 Q4 Holiday Tour: Booking Open For Santa, The 5-star Grinch, And Dual Character Experiences Nationwide
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Headline: House of Nova Paints Every Face in Gold at New York Fashion Week

UST's TELL-Seq is a patent-pending transposase-based linked-read library preparation technology that enables short-read 2nd generation DNA sequencing platforms, such as Illumina sequencers, to produce long-range sequencing results (averaging linked-read molecule length greater than 40kb and up to 200kb). With a simple workflow, a sequencing-ready Illumina library can be prepared in PCR tubes in about 3 hours, cost-effective and no special lab equipment needed.

ABOUT UST

Universal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 PCT patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd-generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.

www.universalsequencing.com

Contact
Ru Zheng
***@universalsequencing.com


Source: Universal Sequencing Technology Corporation
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • One Mile North of 8 Mile: KayeDinero Connects Detroit and Asheville on "Nine Mile"
  • Gabby Press Earns High Praise From Feathered Quill About the Unregulated Dangers of Second Generation Corporate AI
  • Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
  • Detroit Roots, Film Scores and Python Shape KayeDinero's Asheville Sound
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Mom Era, Still That Girl: Family Art Tees 25% Off
  • Fashion vs. Fascism - Because Democracy Should Always Be In Style
  • From Degrassi to Cass Tech: The Unexpected Influences Behind Asheville's KayeDinero
  • Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
  • KayeDinero Takes "Appalachia" Above the Blue Ridge With New Aerial Music Visual
  • Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • Boston Industrial Solutions Introduces Personalized Printing Training
  • Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
  • Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
  • FOCUS Names Mark Phillips Senior Vice President of Business Development
  • Notaron Expands Online Notarization Access Following Wisconsin Approval
  • Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
_catLbl0 _catLbl1

Popular on ncarol.com

  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 161
  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 158
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 142
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate - 137
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 125
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 123
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 123
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 123
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 115
  • Gigasoft 2026 JavaScript Chart Comparison: ProEssentials, Highcharts, SciChart, LightningChart, ECharts - 114

Similar on ncarol.com

  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute